Drug pric­ing watch­dog ICER of­fers ways to in­crease obe­si­ty drug ac­cess

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view, the non­prof­it drug pric­ing watch­dog, re­leased a new re­port on Wednes­day out­lin­ing po­ten­tial fed­er­al pol­i­cy so­lu­tions to in­crease …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER